A Phase I/II, Open-Label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of DZD3969 as Monotherapy or in Combination With Palbociclib in Postmenopausal Female Patients With Estrogen Receptor Positive (ER+) and HER2 Negative (HER2-) Breast Cancer

Status: Not yet recruiting

Phase of Trial: Phase I/II

Latest Information Update: 04 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs DZD 3969 (Primary) ; Palbociclib (Primary)
Indications Advanced breast cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Dizal Pharmaceutical

Most Recent Events

27 Feb 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight